Building in Good Jobs: Linking Workforce Development with Real Estate-Led Economic Development

Municipal governments in the U.S. are increasingly devoting public resources to the redevelopment of abandoned, contaminated or underutilized land. Private sector appetite for new development opportunities and public sector creativity have combined to create building booms in a number of central cities that only a few decades ago were in seemingly irreversible decline. In the midst of this government-supported revitalization, however, both working poverty and chronic unemployment in central cities remain disturbingly high. Without explicit efforts to link property redevelopment with efforts to put un- or underemployed people to work at family-supporting wages, the negative impacts of growth (displacement, housing cost appreciation) often affect the historically disadvantaged far more profoundly than its positive impacts do

Upstream Statin Therapy and Long-Term Recurrence of Atrial Fibrillation after Cardioversion: A Propensity-Matched Analysis

The relationship of statin therapy with recurrence of atrial fibrillation (AF) after cardioversion (CV) has been evaluated by several investigations, which provided conflicting results and particularly long-term data is scarce. We sought to examine whether upstream statin therapy is associated with long-term recurrence of AF after CV. This was a single-center registry study including consecutive AF patients (n = 454) undergoing CV. Cox regression models were performed to estimate AF recurrence comparing patients with and without statins. In addition, we performed a propensity score matched analysis with a 1:1 ratio. Statins were prescribed to 183 (40.3%) patients. After a median follow-up period of 373 (207–805) days, recurrence of AF was present in 150 (33.0%) patients. Patients receiving statins had a significantly lower rate of AF recurrence (log-rank p < 0.001). In univariate analysis, statin therapy was associated with a significantly reduced rate of AF recurrence (HR 0.333 (95% CI 0.225–0.493), p = 0.001), which remained significant after adjustment (HR 0.238 (95% CI 0.151–0.375), p < 0.001). After propensity score matching treatment with statins resulted in an absolute risk reduction of 27.5% for recurrent AF (21 (18.1%) vs. 53 (45.7%); p < 0.001). Statin therapy was associated with a reduced risk of long-term AF recurrence after successful cardioversion

Chronisch Nichtbakterielle Osteomyelitis bei Kindern eine Retrospektive Pilotstudie an der Universitätsklinik für Kinder- und Jugendheilkunde des Allgemeinen Krankenhauses Wien

Hintergrund: Die nichtbakterielle Osteomyelitis ist ein Überbegriff für Krankheiten, welche mit einem nichtbakteriellen entzündlichen Befall eines oder mehrerer Knochen als einziges Symptom oder zusammen mit anderen Symptomen vorkommen. Die chronisch rekurrierende multifokale Osteomyelitis (CRMO) wurde von Giedon et al. zum ersten Mal im Jahr 1972 als „ein Syndrom mit subakuten, chronischen und symmetrisch inflammatorischen Knochenläsionen“ beschrieben.1 Die CRMO betrifft vor allem Kinder und Jugendliche und zeigt eine Inzidenz von 0,4-0,45 pro 100.000 EinwohnerInnen. Bis zum heutigen Zeitpunkt ist die CRMO vor allem eine Ausschlussdiagnose und es existieren keine validierten Biomarker, um diese Erkrankung zu diagnostizieren oder ihren Verlauf zu messen. Die Schwere der Erkrankung wird anhand des klinischen Bildes und der radiologisch gesicherten Läsionen eingeschätzt. Ziel: Aufgrund des ständigen Bestrebens, Biomarker zur Verlaufskontrolle der CRMO zu eruieren, wurde der mögliche Zusammenhang der Blutsenkungsgeschwindigkeit (BSG) mit der absoluten Anzahl an radiologisch gesicherten, von der CRMO betroffenen, Knochen untersucht. Methoden: In einer retrospektiven Datenauswertung wurde der Zusammenhang zwischen der Anzahl von betroffenen Knochen in der Ganzkörper-Magnetresonanztomographie-Untersuchung mit der nächstgelegenen Blutsenkungsgeschwindigkeit (innerhalb von 6 Monaten) untersucht. Resultat: In der Regression nach Spearman konnte kein signifikanter Zusammenhang zwischen BSG und betroffener Knochenanzahl nachgewiesen werden (p = 0,470, Rho = 0,277). Weiters zeigten die untersuchten Biomarker C-reaktives Protein, Interleukin-6, Serum-Amyloid-A und relative Monozytenzahl keine signifikanten Zusammenhänge mit der Anzahl der betroffenen Knochen in der Ganzkörper-Magnetresonanztomographie (p = 0,654, p = 0,716, p = 0,249, p = 0,746). Schlussfolgerung: In dieser Pilotstudie konnte kein Nachweis eines Zusammenhanges zwischen BSG und der Anzahl der von Osteomyelitis betroffenen Knochen gezeigt werden. Die Seltenheit der CRMO bedingt in monozentrischen Studien eine stark limitierte Fallzahl. Bei gleichzeitiger Heterogenität der jeweiligen Patientendaten ist die Untersuchung von Biomarkern schwierig durchzuführen. Eine prospektive, koordinierte Erfassung von Patientendaten in großen multizentrischen Datenbanken wäre für die Untersuchung von Biomarkern zur Diagnosestellung und zur Verlaufskontrolle erforderlich.Backround: The term “nonbacterial osteomyelitis” describes a disease, involving nonbacterial infection of the bone or bone marrow, which can be the only symptom or be combined with other symptoms in other different syndromes. The chronic recurrent multifocal osteomyelitis (CRMO), first described by Giedon et al. in 1972, is the most severe form of nonbacterial osteomyelitis. Giedon et al. described it as a “subacute and chronic “symmetrical” osteomyelitis”. CRMO especially affects children and young adolescents and shows an incidence of about 0,4 0,45 of 100.000 inhabitants. Until this day, CRMO is a diagnosis of exclusion. Therefore, validated diagnostic biomarkers or disease activity parameters are non-existent. The degree of disease severity is evaluated through the physicians opinion according to a combination of the clinical impression and proved radiological lesions. Objective: To investigate the correlation between the erythrocyte sedimentation rate (ESR) and the number of radiologically affected bones. Methods: In a retrospective chart review of 16 patients which were diagnosed of CRMO from June 2007 till April 2018 the available reports of whole-body magnetic resonance images were matched with the closest available ESR rate, but within six months. Results: In a linear regression analysis, the association of ESR and affected bones was not significant (p = 0,470, Rho = 0,277). Other examined markers as C-reactive-peptide (CRP), serum-amyloid-A (SAA), interleukine-6 (IL-6) and the relative monocytes were not statistically significant in linear regression analysis (p = 0,654, p = 0,716, p = 0,249, p = 0,746). Conclusion: In this pilot study we could not show a significant association of ESR and number of affected bones. Other evaluated biomarkers also did not show significant results. Further studies with larger patient groups are necessary to assess useful biomarkers for CRMO. As CRMO is a rare disease, international multicentric collaborations are necessary to provide the possibility for proper investigation of diagnostic biomarkers as well as biomarkers used as disease activity parameters.eingereicht von Laura StixAbweichender Titel laut Übersetzung der Verfasserin/des VerfassersMedizinische Universität Wien, Diplomarb., 2018(VLID)251349

Upstream Statin Therapy and Long-Term Recurrence of Atrial Fibrillation after Cardioversion: A Propensity-Matched Analysis

The relationship of statin therapy with recurrence of atrial fibrillation (AF) after cardioversion (CV) has been evaluated by several investigations, which provided conflicting results and particularly long-term data is scarce. We sought to examine whether upstream statin therapy is associated with long-term recurrence of AF after CV. This was a single-center registry study including consecutive AF patients (n = 454) undergoing CV. Cox regression models were performed to estimate AF recurrence comparing patients with and without statins. In addition, we performed a propensity score matched analysis with a 1:1 ratio. Statins were prescribed to 183 (40.3%) patients. After a median follow-up period of 373 (207–805) days, recurrence of AF was present in 150 (33.0%) patients. Patients receiving statins had a significantly lower rate of AF recurrence (log-rank p < 0.001). In univariate analysis, statin therapy was associated with a significantly reduced rate of AF recurrence (HR 0.333 (95% CI 0.225–0.493), p = 0.001), which remained significant after adjustment (HR 0.238 (95% CI 0.151–0.375), p < 0.001). After propensity score matching treatment with statins resulted in an absolute risk reduction of 27.5% for recurrent AF (21 (18.1%) vs. 53 (45.7%); p < 0.001). Statin therapy was associated with a reduced risk of long-term AF recurrence after successful cardioversion

Upstream Statin Therapy and Long-Term Recurrence of Atrial Fibrillation after Cardioversion: A Propensity-Matched Analysis

The relationship of statin therapy with recurrence of atrial fibrillation (AF) after cardioversion (CV) has been evaluated by several investigations, which provided conflicting results and particularly long-term data is scarce. We sought to examine whether upstream statin therapy is associated with long-term recurrence of AF after CV. This was a single-center registry study including consecutive AF patients (n = 454) undergoing CV. Cox regression models were performed to estimate AF recurrence comparing patients with and without statins. In addition, we performed a propensity score matched analysis with a 1:1 ratio. Statins were prescribed to 183 (40.3%) patients. After a median follow-up period of 373 (207–805) days, recurrence of AF was present in 150 (33.0%) patients. Patients receiving statins had a significantly lower rate of AF recurrence (log-rank p &lt; 0.001). In univariate analysis, statin therapy was associated with a significantly reduced rate of AF recurrence (HR 0.333 (95% CI 0.225–0.493), p = 0.001), which remained significant after adjustment (HR 0.238 (95% CI 0.151–0.375), p &lt; 0.001). After propensity score matching treatment with statins resulted in an absolute risk reduction of 27.5% for recurrent AF (21 (18.1%) vs. 53 (45.7%); p &lt; 0.001). Statin therapy was associated with a reduced risk of long-term AF recurrence after successful cardioversion

Upstream Statin Therapy and Long-Term Recurrence of Atrial Fibrillation after Cardioversion: A Propensity-Matched Analysis

The relationship of statin therapy with recurrence of atrial fibrillation (AF) after cardioversion (CV) has been evaluated by several investigations, which provided conflicting results and particularly long-term data is scarce. We sought to examine whether upstream statin therapy is associated with long-term recurrence of AF after CV. This was a single-center registry study including consecutive AF patients (n = 454) undergoing CV. Cox regression models were performed to estimate AF recurrence comparing patients with and without statins. In addition, we performed a propensity score matched analysis with a 1:1 ratio. Statins were prescribed to 183 (40.3%) patients. After a median follow-up period of 373 (207–805) days, recurrence of AF was present in 150 (33.0%) patients. Patients receiving statins had a significantly lower rate of AF recurrence (log-rank p < 0.001). In univariate analysis, statin therapy was associated with a significantly reduced rate of AF recurrence (HR 0.333 (95% CI 0.225–0.493), p = 0.001), which remained significant after adjustment (HR 0.238 (95% CI 0.151–0.375), p < 0.001). After propensity score matching treatment with statins resulted in an absolute risk reduction of 27.5% for recurrent AF (21 (18.1%) vs. 53 (45.7%); p < 0.001). Statin therapy was associated with a reduced risk of long-term AF recurrence after successful cardioversion